DHT Holdings Inc. vs Neurocrine Biosciences Inc — how do they compare? DHT Holdings Inc. trades at $24.68 (market cap $4.02B), while Neurocrine Biosciences Inc trades at $143.97 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is far larger — about 3.6× DHT Holdings Inc.'s market cap, and DHT Holdings Inc. pays a 19.57% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold DHT Holdings Inc. for 1 Days and Neurocrine Biosciences Inc for 23 Days on average.
| DHT | NBIX | |
|---|---|---|
Market Cap | $4.02B | $14.36B |
Volume | 5,493,801 | 1,237,180 |
Sector | Industrials | Health |
52-Week High | $24.93 | $185.50 |
52-Week Low | $11.20 | $123.10 |
Typical Hold Time | 1 Days | 23 Days |
Enterprise Value | $4.29B | $14.37B |
Dividend Yield | 19.57% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Neurocrine Biosciences (NBIX) trades at $142.44, down 0.72% with bearish technical signals but strong fundamentals including three consecutive quarterly EPS beats. The company shows robust profitability with 20.91% net margin and 22.09% ROE, supported by growing revenue from $2.9B to $3.4B projected. Recent news highlights pipeline development and conference participation.
Wall Street maintains strong bullish sentiment with 86% buy ratings and $204.18 consensus target, representing 43% upside. Key risks include INGREZZA pricing pressure in 2029 and execution challenges as the company diversifies beyond its main product. The stock offers growth potential but faces near-term technical headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
DHT Holdings operates a fleet of crude oil tankers that trade on international routes. Its fleet consists of very large crude carriers, or VLCCs.
Read more on DHT →Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →